Nasdaq: COAG · Listed May 1, 2026
Hemab Therapeutics Holdings IPO
IPO price
$18.00
Hemab Therapeutics Holdings (COAG) priced its IPO at $18.00 a share and has traded on Nasdaq since May 1, 2026.
COAG today$37.95+110.83%since IPO15-min delayed · as of 4:02:06 AM EST on Nov 19, 2026
See the COAG quoteFirst trading day · May 1, 2026
- IPO price
- $18.00
- the top of the range of $16 to $18
- First trade
- $27.00
- +50.00% from the IPO price
- First-day last trade
- $34.50
- +91.67% from the IPO price, regular session
- Raise
- $301.5M
- before the underwriters' option
These numbers are from the first trading day, May 1, 2026.
How COAG did against the market
COAG against the market, from its first trade at 12:30 ET to the last trade of the session.
- COAG from its first trade
- +27.78%
- Against the market (QQQ)
- +27.8 pts
COAG rose 27.8% from its first trade to the last trade of the session. That is 27.8 points better than the market.
Same-day moves do not show that COAG caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
COAG against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
COAG against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Hemab Therapeutics Holdings '26 | $301.5M | +50.00% | +91.67% | +42.03% | +38.78% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Hemab Therapeutics Holdings IPO offers 16.75M shares to raise $301.5M, before any underwriters' option.
- Expected price range
- $16 to $18
- IPO price
- $18.00
- Shares offered
- 16.75M
- Money raised
- $301.5M
- Listing date
- May 1, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Hemab Therapeutics Holdings$301.5M
Where COAG ranks
Hemab Therapeutics Holdings's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- COAG$1.83B
COAG news
The latest news and headlines about Hemab Therapeutics Holdings (COAG).
- Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 CongresspositiveGlobeNewswire Inc.· Jul 12, 2026
- Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharespositiveBenzinga· May 4, 2026
Filings and the company
What Hemab Therapeutics Holdings has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Hemab Therapeutics Holdings discloses to the SEC on Form 8-K.
- Quarterly earningsNov 10, 2026
On November 10, 2026, Hemab Therapeutics Holdings, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2026.
- Executive compensation changeSep 24, 2026
Ms. Walbert will receive annual cash compensation of $40,000 as a member of the Board, additional annual cash compensation of $10,000 as a member of the Audit Committee, annual equity grants in accordance with the non-employee director compensation policy and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings.
- Director departureMay 11, 2026
On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the "Company") of her decision to resign as a member of the Company's board of directors (the "Board"), effective immediately. Dr. Tadvalkar's resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
- Public offeringMay 4, 2026
On May 4, 2026, the Company completed its IPO of 19,262,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,512,500 additional shares of common stock, at a public offering price of $18.00 per share. The gross proceeds to the Company from the IPO were $346.7 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
About Hemab Therapeutics Holdings
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
- Ticker
- COAG
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Listed
- May 1, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Hemab Therapeutics Holdings IPO price?
$18.00 a share.
When did Hemab Therapeutics Holdings go public?
Hemab Therapeutics Holdings listed on Nasdaq on May 1, 2026 under the ticker COAG.
How much did the Hemab Therapeutics Holdings IPO raise?
$301.5M, before any underwriters' option.
How did Hemab Therapeutics Holdings open on its first day?
COAG first traded at $27.00, +50.00% from the IPO price of $18.00.
How did COAG close on its first day?
Its last regular-session trade was $34.50, +91.67% from the IPO price of $18.00.
What was the COAG first-day trading range?
$27.00 to $36.61 in the regular session.
How many COAG shares traded on the first day?
4.03M shares in the regular session.
How many shares did Hemab Therapeutics Holdings sell in its IPO?
16.75M shares.
How did COAG do against the market on its first day?
COAG rose 27.8% from its first trade to the last trade of the session. That is 27.8 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is COAG listed on?
Hemab Therapeutics Holdings lists on Nasdaq under the ticker COAG.
Build with Massive
Get the COAG data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/COAG/range/5/minute |
| Market cap | /v3/reference/tickers/COAG |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.